Biodexa Pharmaceuticals (BDRX) Income from Continuing Operations (2013 - 2025)

Biodexa Pharmaceuticals has disclosed Income from Continuing Operations across 13 years of filings, most recently posting -$5.3 million for Q2 2025.

• In Q2 2025, Income from Continuing Operations changed N/A year-over-year to -$5.3 million; the TTM figure through Jun 2025 stood at -$24.0 million (changed N/A YoY), while the FY2025 annual figure was -$8.7 million, down 9.19% from the prior year.
• Income from Continuing Operations came in at -$5.3 million for Q2 2025 at Biodexa Pharmaceuticals, down from -$4.6 million in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of -$4.6 million in Q4 2024 to a low of -$10.1 million in Q4 2022.
• Average Income from Continuing Operations over 5 years is -$6.5 million, with a median of -$5.2 million recorded in 2021.
• Year-over-year, Income from Continuing Operations surged 78.13% in 2021 and dropped 18.62% in 2022.
• Over 5 years, Income from Continuing Operations stood at -$8.5 million in 2021, then declined by 18.62% to -$10.1 million in 2022, then climbed by 8.39% to -$9.3 million in 2023, then jumped by 50.84% to -$4.6 million in 2024, then retreated by 16.0% to -$5.3 million in 2025.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were -$5.3 million in Q2 2025, -$4.6 million in Q4 2024, and -$9.3 million in Q4 2023.